The 10 most recent market catalysts affecting $KPTI, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 11, 2026
Corporate Catalyst
Bearish
Impact 85
Karyopharm Therapeutics shares are trading lower after the company announced a Forbearance Agreement and Limited Waiver to gain time to advance its myelofibrosis program, negotiate with lenders, explore strategic options, or raise equity.
This headline is a major negative corporate catalyst for Karyopharm Therapeutics. A forbearance agreement indicates the company is struggling to meet its debt obligations, raising …
Sep 11, 2026
Corporate Catalyst
Neutral
Impact 85
Karyopharm Therapeutics Signs Forbearance Agreement, Limited Waiver To Indentures For Additional Time To Advance Its Myelofibrosis Program; Did Not Pay $15.8M Due Under Sept. 10 Credit Agreement
Karyopharm Therapeutics (KPTI) disclosed that it did not make a $15.8 million payment due under its September 10 credit agreement, leading to a forbearance agreement and limited wa…
Aug 31, 2026
Corporate Catalyst
Neutral
Impact 85
Karyopharm Therapeutics Submits sNDA To FDA Seeking Accelerated Approval For XPOVIO In Combination With Ruxolitinib For Patients With Myelofibrosis
Karyopharm Therapeutics (KPTI) has submitted an sNDA to the FDA for accelerated approval of XPOVIO for myelofibrosis, a significant step towards expanding the drug's indications. T…
Aug 13, 2026
Corporate Catalyst
Bearish
Impact 55
Karyopharm Therapeutics Affirms FY2026 Sales Guidance of $130.000M-$150.000M vs $133.736M Est
Karyopharm Therapeutics filed an 8-K to affirm its fiscal year 2026 sales guidance, keeping it at $130 million to $150 million. This is a neutral event as the guidance remains unch…
Aug 13, 2026
Corporate Catalyst
Bullish
Impact 65
Karyopharm Therapeutics Q2 EPS $(2.32) Misses $(1.28) Estimate, Sales $33.432M Beat $32.188M Estimate
The substantial EPS miss for Karyopharm Therapeutics (KPTI) indicates a significant profitability challenge, which will likely overshadow the modest revenue beat. Investors will fo…
Jul 31, 2026
Corporate Catalyst
Bearish
Impact 95
Karyopharm Therapeutics shares are trading lower after the company announced topline results from its Phase 3 XPORT-EC-042 trial did not meet its primary endpoint of progression free survival. Also, Piper Sandler lowered its price target on the stock from $16 to $7.
The failure of a Phase 3 clinical trial to meet its primary endpoint is a major negative catalyst for a biotechnology company. This directly impacts Karyopharm's future revenue pot…
Jul 31, 2026
Corporate Catalyst
Bearish
Impact 75
HC Wainwright & Co. Downgrades Karyopharm Therapeutics to Neutral, Lowers Price Target to $3
HC Wainwright & Co. analyst Robert Burns downgraded Karyopharm Therapeutics from a 'Buy' to a 'Neutral' rating, simultaneously slashing the price target from $13 to $3. This drasti…
Jul 31, 2026
Corporate Catalyst
Bearish
Impact 95
Karyopharm Stock (KPTI) Crashes After Hours: Here's What's Driving the Move
Karyopharm Therapeutics experienced a massive stock price drop after its Phase 3 trial for selinexor in endometrial cancer did not achieve its primary endpoint. This is a critical …
Jul 30, 2026
Corporate Catalyst
Bullish
Impact 75
12 Health Care Stocks Moving In Thursday's After-Market Session
The filing highlights substantial after-market price movements for a dozen healthcare companies, with several experiencing double-digit percentage changes. These movements are larg…
Jul 30, 2026
Corporate Catalyst
Bearish
Impact 95
Karyopharm Therapeutics shares are trading lower after the company announced topline results from its Phase 3 XPORT-EC-042 trial did not meet its primary endpoint of progression free survival.
The failure of a Phase 3 clinical trial to meet its primary endpoint is a major negative catalyst for any biotechnology company, especially when it involves a drug candidate consid…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.